Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. It is indicated for primary open‑angle glaucoma and ocular hypertension in adults, helping to lower intra‑ocular pressure with once‑daily instillation.\n\nGNH India supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to lower intraocular pressure in glaucoma and ocular hypertension.\n\nPrimary open‑angle glaucoma: reduces intraocular pressure and slows disease progression.\nOcular hypertension: lowers elevated eye pressure to help prevent development of glaucoma.

Latanoprost may cause ocular and systemic reactions.\n\nCommon Side Effects:\n- Eye redness or hyperemia\n- Increased eyelash length and thickness\n- Darkening of iris pigment\n- Mild eye irritation or foreign‑body sensation\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., angio‑edema)\n- Uveitis or intraocular inflammation\n- Corneal edema or keratitis\n- Persistent eye pain or vision loss

Before using Latanoprost, consider the following precautions.\n\nMonitor intraocular pressure: measure pressure regularly after initiation.\nAssess for ocular infections: avoid use if active infection is present.\nHistory of uveitis: monitor closely for inflammation.\nAvoid concurrent use with other prostaglandin analog eye drops: may increase side‑effects.\nStore at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents.\n\nMajor Interactions (Avoid):\n- Concurrent use with other prostaglandin analog eye drops: additive IOP‑lowering effect.\n- Use with cycloplegic agents: may reduce efficacy.\n- Combination with ocular anesthetics: increased risk of corneal toxicity.\n\nModerate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory eye drops: may affect ocular surface.\n- Systemic carbonic anhydrase inhibitors: additive IOP reduction.